Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection

Vaccine

Volumn 29, Issue 5, 2011, Pages 1082-1089

  Kang, Tae Heung ^a   Monie, Archana ^a   Wu, Lee S F ^a   Pang, Xiaowu ^b   Hung, Chien Fu ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b HOWARD UNIVERSITY COLLEGE OF DENTISTRY   (United States)

Author keywords

CpG; Electroporation; Human papillomavirus (HPV); Protein based vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; OVA PROTEIN; PROTEIN BASED VACCINE; PROTEIN E7; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; DRUG POTENCY; ELECTROPORATION; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; ELECTROPORATION; FEMALE; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; VACCINATION; VACCINES, SUBUNIT;

EID: 78751574264     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.063     Document Type: Article

References (37)

1. Hung C.F., Ma B., Monie A., Tsen S.W., Wu T.C. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 2008, 8(4):421-439.
2. Roden R.B., Monie A., Wu T.C. Opportunities to improve the prevention and treatment of cervical cancer. Curr Mol Med 2007, 7(5):490-503.
3. Ressing M.E., van Driel W.J., Brandt R.M., Kenter G.G., de Jong J.H., Bauknecht T., et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000, 23(2):255-266.
4. van Driel W.J., Ressing M.E., Kenter G.G., Brandt R.M., Krul E.J., van Rossum A.B., et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999, 35(6):946-952.
5. Muderspach L., Wilczynski S., Roman L., Bade L., Felix J., Small L.A., et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000, 6(9):3406-3416.
6. Fausch S.C., Da Silva D.M., Kast W.M. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res 2003, 63(13):3478-3482.
7. Gerard C.M., Baudson N., Kraemer K., Ledent C., Pardoll D., Bruck C. Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice. Clin Cancer Res 2001, 7(3):838s-847s.
8. Tomson T.T., Roden R.B., Wu T.C. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Investig Drugs 2004, 5(12):1247-1261.
9. Guermonprez P., Valladeau J., Zitvogel L., Thery C., Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002, 20:621-667.
10. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5(10):987-995.
11. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406(6797):782-787.
12. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4(7):499-511.
13. Akira S. Toll-like receptors and innate immunity. Adv Immunol 2001, 78:1-56.
14. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev 2006, 5(6):471-484.
15. Deng J.C., Zeng X., Newstead M., Moore T.A., Tsai W.C., Thannickal V.J., et al. STAT4 is a critical mediator of early innate immune responses against pulmonary Klebsiella infection. J Immunol 2004, 173(6):4075-4083.
16. Rees D.G., Gates A.J., Green M., Eastaugh L., Lukaszewski R.A., Griffin K.F., et al. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res 2005, 65(2):87-95.
17. Woo S.J., Kim C.H., Park M.Y., Kim H.S., Sohn H.J., Park J.S., et al. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity. Cancer Sci 2008, 99(5):1034-1039.
18. Xiao Y., Aldaz-Carroll L., Ortiz A.M., Whitbeck J.C., Alexander E., Lou H., et al. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 2007, 25(7):1214-1224.
19. Standley S.M., Mende I., Goh S.L., Kwon Y.J., Beaudette T.T., Engleman E.G., et al. Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity. Bioconjug Chem 2007, 18(1):77-83.
20. Zwaveling S., Ferreira Mota S.C., Nouta J., Johnson M., Lipford G.B., Offringa R., et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002, 169(1):350-358.
21. Ahmad S., Casey G., Sweeney P., Tangney M., O'Sullivan G.C. Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genetic Vaccines Ther 2010, 8(1):1.
22. Zhao Y.L., Murthy S.N., Manjili M.H., Guan L.J., Sen A., Hui S.W. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine 2006, 24(9):1282-1290.
23. Ohlschlager P., Spies E., Alvarez G., Quetting M., Groettrup M. The combination of TLR-9 adjuvantation and electroporation mediated delivery enhances in vivo anti-tumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer 2011, 128(2):473-481.
24. Mir L.M., Bureau M.F., Gehl J., Rangara R., Rouy D., Caillaud J.M., et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999, 96(8):4262-4267.
25. Aihara H., Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998, 16(9):867-870.
26. Kang T.H., Lee J.H., Song C.K., Han H.D., Shin B.C., Pai S.I., et al. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res 2007, 67(2):802-811.
27. Best S.R., Peng S., Juang C.M., Hung C.F., Hannaman D., Saunders J.R., et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009, 27(40):5450-5459.
28. Kim T.W., Hung C.F., Ling M., Juang J., He L., Hardwick J.M., et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003, 112(1):109-117.
29. Lin K.-Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996, 56:21-26.
30. Kim T.W., Hung C.F., Boyd D.A., He L., Lin C.T., Kaiserman D., et al. Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res 2004, 64(1):400-405.
31. Kim D., Hung C.F., Wu T.C. Monitoring the trafficking of adoptively transferred antigen-specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther 2007, 18(7):575-588.
32. Kang T.H., Chung J.Y., Monie A., Pai S.I., Hung C.F., Wu T.C. Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA. Gene Ther 2010, 17(4):531-540.
33. Cheng W.-F., Hung C.-F., Chai C.-Y., Hsu K.-F., He L., Ling M., et al. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol 2001, 75:2368-2376.
34. Cheng W.F., Hung C.F., Chai C.Y., Hsu K.F., He L., Ling M., et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001, 108(5):669-678.
35. Roux S., Bernat C., Al-Sakere B., Ghiringhelli F., Opolon P., Carpentier A.F., et al. Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother 2008, 57(9):1291-1300.
36. Shirota H., Petrenko L., Hong C., Klinman D.M. Potential of transfected muscle cells to contribute to DNA vaccine immunogenicity. J Immunol 2007, 179(1):329-336.
37. Tukey J.W. Some thoughts on clinical trials, especially problems of multiplicity. Science 1977, 198(4318):679-684.